Back
ESC Professional Premium Access

Dapagliflozin versus empagliflozin and major adverse cardiovascular events in type 2 diabetes: a nationwide cohort study

Session: Diabetes, obesity, and the heart
Topic: Antidiabetic Pharmacotherapy
Speaker: Doctor A. Alhakak (Copenhagen, DK)
Event: ESC Congress 2024

Congress Presentation

Add to my library

Like

About the speaker

Doctor Amna Alhakak

Rigshospitalet - Copenhagen University Hospital, Copenhagen (Denmark)
0 follower

6 more presentations in this session

GLP1-RA versus DPP4 inhibitors on cardiovascular outcomes: A three-year real-world analysis

Speaker: Doctor K. Soerensen (Copenhagen, DK)

Access
Abstract
Slides
Video
Like
Thumbnail

The role of sodium-glucose cotransporter 2 (SGLT2) inhibitors in epicardial adipose tissue modulation: a meta-analysis

Speaker: Doctor P. Theofilis (Athens, GR)

Access
Abstract
Slides
Video
Like
Thumbnail

The effect of Glucagon-like peptide-1 receptor agonists on cardiovascular outcomes in type 2 diabetes mellitus patients with coronary artery disease

Speaker: Doctor J. Tjerkaski (Stockholm, SE)

Access
Abstract
Slides
Video
Like
Thumbnail

Impact of SGLT2 inhibitor dapagliflozin on myocardial protein profile in rats with long-standing Type 1 diabetes mellitus

Speaker: Doctor E. Rodrigues (Botucatu, BR)

Access
Abstract
Slides
Video
Like
Thumbnail

Body mass index and clinical outcomes in patients with diabetes and stable coronary artery disease in THEMIS

Speaker: Doctor M. Pareek (Copenhagen, DK)

Access
Abstract
Slides
Video
Like
Thumbnail

Access the full session

Diabetes, obesity, and the heart

Speakers: Doctor A. Alhakak, Doctor K. Soerensen, Doctor P. Theofilis, Doctor J. Tjerkaski, Doctor E. Rodrigues...
Access
Like
Thumbnail

About the event

Image

ESC Congress 2024

30 August - 2 September 2024

Sessions Presentations

Congress
logo Image

ESC 365 is supported by

logo Bristol Myers Squibb Explore sponsored resources
logo Novo Nordisk Explore sponsored resources